Breast Cancer | Specialty

Considering the Oral SERD and PROTAC Toxicity Profiles

September 24th 2025

Panelists discuss how the well-tolerated safety profiles of oral selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs), despite some low-grade toxicities such as bradycardia and photopsia, make them attractive options, with treatment decisions potentially influenced by specific adverse effect considerations and monitoring requirements.

Dr Tolaney on the Potential Role for Sac-TMT With/Without Pembrolizumab in HR+, HER2– Breast Cancer

September 22nd 2025

Sara M. Tolaney, MD, MPH, discusses the potential role of Sac-TMT with/without pembrolizumab in HR+, HER2– breast cancer.

Giredestrant Plus Everolimus Meets Coprimary PFS End Points in Post–CDK Inhibitor ER+/HER2– Breast Cancer

September 22nd 2025

Giredestrant plus everolimus improved PFS vs SOC endocrine therapy plus everolimus in CDK4/6 inhibitor–pretreated, ER-positive breast cancer.

FDA Approves Subcutaneous Pembrolizumab for Solid Tumors

September 19th 2025

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

FDA Approves 2 Denosumab Biosimilars in High Fracture Risk Populations, Including in Breast and Prostate Cancer

September 17th 2025

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

Combination Treatment Options for Patients With ESR1 Mutation and Comutations

September 17th 2025

Panelists discuss how treatment approaches for patients with both ESR1 mutations and PI3K pathway alterations currently rely on single-agent elacestrant for slow-growing disease or doublet therapies for more aggressive cases, with the field rapidly evolving toward targeted combination therapies.

Emerging Oral SERD and PROTAC Treatment Options as Monotherapy and in Combination

September 17th 2025

Panelists discuss how proteolysis-targeting chimera (PROTAC) agents such as vepdegestrant offer a different mechanism of action compared with oral selective estrogen receptor degrader (SERDs), with promising clinical activity in ESR1-mutant tumors and the need for more data on optimal sequencing strategies.

Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer

September 17th 2025

Neoadjuvant palbociclib plus endocrine therapy did not improve PEPI scores in operable hormone receptor–positive breast cancer.

Evaluating Longitudinal ctDNA Testing for Molecular Progression During CDK4/6 Inhibitor Therapy

September 8th 2025

Panelists discuss how longitudinal surveillance testing could enable treatment interventions based on molecular progression (ESR1 mutations) rather than waiting for radiographic progression, though questions remain about overall survival impact.

The Impact of Oral SERDs on the Changing Treatment Landscape

September 8th 2025

Panelists discuss how oral selective estrogen receptor degraders (SERDs) such as elacestrant are changing treatment for patients experiencing progression on CDK4/6 inhibitors, with current approval for ESR1-mutant tumors and anticipation of additional approvals for other oral SERDs in development.

Dr O’Shaughnessy on the Utility of the MammaPrint Assay in HR+ Breast Cancer

September 5th 2025

Joyce O’Shaughnessy, MD, discussed data that support the use of the MammaPrint assay in predicting chemotherapy benefit in HR-positive breast cancer.

Dr McArthur on Data Supporting the Ongoing Investigation of Palazestrant in ER+, HER2– Breast Cancer

September 3rd 2025

Heather McArthur, MD, MPH, FASCO, discusses data from a phase 1/2 study evaluating palazestrant in ER+, HER2– advanced or metastatic breast cancer.

OncLive’s August EMA Regulatory Recap: Key EU Approvals in Oncology

September 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

FDA Approves New Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

September 2nd 2025

Revisit Every OncLive On Air Episode From August 2025

September 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

Five Under 5: Top Oncology Videos for the Week of 8/24

August 31st 2025

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 8/24

August 30th 2025

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

Ongoing Trials and Practical Insights Shape CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer

August 30th 2025

Neelam V. Desai, MD, discusses the role of first-line CDK4/6 inhibitors in HR-positive, HER2-negative and HER2-positive metastatic breast cancer.

Dr Desai on Research Informing Upfront CDK 4/6 Inhibitor Use in HR+/HER2– Breast Cancer

August 29th 2025

Neelam Desai, MD, discusses the current body of evidence for CDK 4/6 inhibitor use in metastatic HR-positive, HER2-negative breast cancer.

Multidisciplinary Teams Tailor Therapies to Reduce Surgical Burden in Breast Cancer

August 29th 2025

Tari A. King, MD, FACS, FSSO, FASCO, discusses the importance of multidisciplinary breast cancer management and the potential to de-escalate treatment.